Key points are not available for this paper at this time.
BACKGROUND: Breast cancer (BC) treatment is rapidly evolving with new and costly therapeutics. Existing costing models have a limited ability to capture current treatment costs. We used an Activity-Based Costing (ABC) method to determine a per-case cost for BC treatment by stage and molecular subtype. METHODS: ABC was used to proportionally integrate multidisciplinary evidence-based patient and provider treatment options for BC, yielding a per-case cost for the total duration of treatment by stage and molecular subtype. Diagnostic imaging, pathology, surgery, radiation therapy, systemic therapy, inpatient, emergency, home care and palliative care costs were included. RESULTS: BC treatment costs were higher than noted in previous studies and varied widely by molecular subtype. Cost increased exponentially with the stage of disease. The per-case cost for treatment (2023C) for DCIS was C 14, 505, and the mean costs for all subtypes were C 39, 263, C 76, 446, C 97, 668 and C 370, 398 for stage I, II, III and IV BC, respectively. Stage IV costs were as high as C 516, 415 per case. When weighted by the proportion of molecular subtype in the population, case costs were C 31, 749, C 66, 758, C 111, 368 and C 289, 598 for stage I, II, III and IV BC, respectively. The magnitude of cost differential was up to 10. 9 times for stage IV compared to stage I, 4. 4 times for stage III compared to stage I and 35. 6 times for stage IV compared to DCIS. CONCLUSION: The cost of BC treatment is rapidly escalating with novel therapies and increasing survival, resulting in an exponential increase in treatment costs for later-stage disease. We provide real-time, case-based costing for BC treatment which will allow for the assessment of health system economic impacts and an accurate understanding of the cost-effectiveness of screening.
Wilkinson et al. (Sat,) studied this question.